Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022
Citius Pharmaceuticals, a late-stage biopharmaceutical company focused on critical care products, will be represented by Chairman and CEO Leonard Mazur at the Dawson James Securities Small Cap Growth Conference on October 12, 2022, at 3:30 PM ET in Jupiter, Florida. The live presentation will be available via webcast, and a replay will be accessible for 90 days on the Company’s Investors website.
- None.
- None.
CRANFORD, N.J., Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will be presenting at the Dawson James Securities Small Cap Growth Conference on October 12, 2022.
Conference Details: | |
Date: | October 12, 2022 |
Time: | 3:30PM ET |
Location: | Wyndham Grand Hotel in Jupiter, Florida |
Live presentation: | Available for viewing live on October 12 via webcast. |
Webcast replay: | Available for the following 90 days on the Company's Investors website. |
One-on-one Meetings: | To request a meeting, please contact your Dawson James representative. |
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), for which a BLA has been submitted. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids. The Company anticipates completing enrollment in the Halo-Lido trial by the end of 2022. For more information, please visit https://www.citiuspharma.com/.
Investor Contact:
Ilanit Allen
Vice President, Corporate Communications and Investor Relations
T: 908-967-6677 x113
E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-dawson-james-securities-small-cap-growth-conference-on-october-12-2022-301643174.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When is Citius Pharmaceuticals presenting at the Dawson James Conference?
What time will Citius Pharmaceuticals' presentation start?
Where is the Dawson James Securities Small Cap Growth Conference held?
How can I watch Citius Pharmaceuticals' presentation live?
Will there be a replay of the Citius Pharmaceuticals presentation?
